Sanford J. Madigan
Sandy brings over 20 years of experience to roles at COI, Ankasa and Anexigen and has a track record of building early-stage companies, licensing technologies, providing strategic direction, and negotiating partnerships and acquisitions.
Prior to his current roles, Sandy was co-founder and chief executive officer of Strategic Enzyme Applications, a clean technology company established as a strategic relationship with Monsanto. Previously, he served in various venture-backed biotechnology companies; participating as a founder, director and/or senior manager in Ambit (AMBI), Xenopharm (acquired by Deltagen), X-Ceptor (acquired by Exelixis) and SIBIA Neurosciences (acquired by Merck).
Prior to his current roles, Sandy was co-founder and chief executive officer of Strategic Enzyme Applications, a clean technology company established as a strategic relationship with Monsanto. Previously, he served in various venture-backed biotechnology companies; participating as a founder, director and/or senior manager in Ambit (AMBI), Xenopharm (acquired by Deltagen), X-Ceptor (acquired by Exelixis) and SIBIA Neurosciences (acquired by Merck).
Country:
USA